Breast Cancer Immuno-Oncology
Clinical research at the Champalimaud Clinical Centre includes studies in triple-negative breast cancer, with attention to tumour-infiltrating lymphocytes, immune activation, and checkpoint inhibitor-based treatment strategies.
- Triple-negative breast cancer
- Immunotherapy and chemotherapy
- T-cell subpopulations
- Tumour immune microenvironment
The centre’s breast cancer studies focus on locally advanced and high-risk disease, with interest in identifying immune-related features linked to treatment response.
Ovarian Cancer Treatment Guidance
The sponsor is involved in relapsed ovarian cancer research, including work on treatment selection using predictive approaches intended to support therapeutic decision-making in oncology.
- Relapsed ovarian cancer
- Predictive treatment models
- Progression-free survival
- Standard-of-care comparison
These studies reflect an interest in linking clinical outcomes with tools that may help guide care in recurrent disease.
Metastatic Breast Cancer and Symptomatic Disease
Research activity also extends to metastatic breast cancer, including patients with malignant pleural effusion and ascites, where the focus is on treatment effectiveness and disease control.
- Metastatic breast cancer
- Malignant pleural effusion
- Ascites
- Oncology supportive disease settings
The centre’s interest in this area covers advanced disease presentations and their relevance to survival outcomes and treatment choice.
